



INDIAN PHARMACOPOEIA COMMISSION

National Coordination Centre- Pharmacovigilance Programme of India (PvPI)

MINISTRY OF HEALTH & FAMILY WELFARE, GOVERNMENT OF INDIA

SECTOR-23, RAJ NAGAR, GHAZIABAD- 201 002.

Tel No: 0120- 2783392, 2783400, 2783401,6582849 (Direct), Fax: 0120-2783311

e-mail: pvpi@ipcindia.net, ipclab@vsnl.net, Web: www.ipc.gov.in

File No. IPC/NCC-PvPI/DSA/2016-17/

May 2016

Drug Safety Alert

The preliminary analysis of SUSARs from the PvPI database reveals that the following drugs are associated with the risks as given below.

Table

S.No	Suspected Drugs	Indication	Adverse Reactions
1	Peginterferon alpha-2a	Chronic active Hepatitis B & C	Vasculitis
2	Piperacillin & Tazobacam	In the treatment of lower RTI/UTI/intra abdominal infections, skin and skin structure infections, bacterial septicaemia polymicrobial infection	Vision abnormal
3	Mometasone Furoate, Topical	Steroid responsive dermatitis , eczema, or atopic dermatitis	Hypertrichosis/Hirsutism, Skin depigmentation

Health care professionals, Patients/Consumers are advised to closely monitor the possibility of the above adverse events while prescribing/consuming above suspected drugs and report to the NCC-PvPI either by filling of Suspected Adverse Drug Reactions Reporting Form/ Medicines Side Effect Reporting Form for Consumer (<http://www.ipc.gov.in>) or by PvPI Helpline No. **1800-180-3024**.

“Let us join hands with PvPI to ensure patients safety”

ADR Reporting Help line (Toll Free): 1800-180-3024